Keyphrases
ChAdOx1 nCoV-19
100%
Immunogenicity
74%
COVID-19
69%
COVID-19 Vaccine
48%
AZD1222
45%
Antibody Response
43%
Two-dose
32%
Randomized Controlled Trial
29%
Booster Dose
27%
BNT162b2
26%
Chad
25%
Randomized Trial
25%
Third Dose
25%
ChAdOx1 nCoV-19 Vaccine
25%
Prime-boost
20%
SARS-CoV-2 Infection
19%
Reactogenicity
19%
Neutralizing Antibodies
18%
Virus Neutralization
18%
Second Dose
18%
T Cell Response
16%
SARS-CoV-2 Vaccine
16%
Vaccine Effectiveness
15%
Vaccination
15%
Oxford
15%
Plaque Reduction Neutralization
14%
South Africa
14%
Brazil
14%
Binding Antibodies
14%
Asymptomatic Infection
14%
Interim Analysis
14%
MRNA-1273
13%
Half-dose
12%
Author Names
12%
SARS-CoV-2 Neutralizing Antibody
12%
Pathological Outcomes
12%
Ferret
12%
SARS-CoV-2 Challenge
12%
CCHF Virus
12%
Single-dose Treatment
12%
Animal Sera
12%
Non-inferiority Trial
12%
Fourth Dose
12%
Phase II Trial
12%
Correlates of Protection
12%
Microneutralization
12%
Antibody Detection
12%
Domestic Animals
12%
Vaccine Trial
12%
Phase 1/2 Clinical Trial
12%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
73%
COVID-19
56%
Immunogenicity
51%
COVID-19 Vaccine
33%
Infection
31%
Booster Dose
29%
Single Drug Dose
27%
Neutralization
26%
Randomized Controlled Trial
25%
Antibody Response
24%
Vaccine Efficacy
23%
Neutralizing Antibody
21%
Adverse Event
20%
Reactogenicity
16%
Medicine
16%
Interim Analysis
16%
Virus Neutralization
15%
Clinical Trial
15%
Nucleic Acid Amplification
15%
Noninferiority Trial
12%
T Cell
12%
Pooled Analysis
12%
Group Trial
12%
Messenger RNA
12%
Virus Particle
10%
Wassermann Test
10%
Enzyme Linked Immunosorbent Assay
9%
Low Drug Dose
8%
Conjugate Vaccine
6%
Diseases
6%
Immune Response
5%
Table Salt
5%
Intention-to-Treat Analysis
5%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
76%
COVID-19
40%
Immunogenicity
33%
Neutralization
31%
Spike
26%
Antibody Response
25%
Booster Dose
25%
Neutralizing Antibody
24%
Wild Type
17%
Virus
17%
Virus Neutralization
16%
ELISA
15%
Mustela Putorius Furo
12%
Rhesus Monkey
12%
Inactivated Vaccine
12%
Crimean-Congo Hemorrhagic Fever Virus
12%
Binding Antibody
12%
Domestic Animal
12%
Plaque Reduction Neutralization Test
10%
Monoclonal Antibody
8%
Vaccine Efficacy
8%
Immune Response
7%
Virus Spike
6%